Chantix unsuitable for first-line smoking cessation use, study finds

The poor safety profile of the smoking-cessation drug varenicline (Chantix) makes it unsuitable for first-line use, according to a new study. Varenicline, which already carries a "black box warning" from the U.S. Food and Drug Administration, showed a substantially increased risk of reported depression or suicidal behavior compared to other smoking-cessation treatments, according to researchers.

Read the whole article on Science Daily

More from Science Daily